Learn More
CONTEXT KRAS mutations play an important role in pancreatic cancer. GNAS mutations were discovered in intraductal papillary mucinous neoplasms (IPMN). OBJECTIVES Our aim was to identify the frequency of KRAS and GNAS mutations in pancreatic cystic neoplasms and pancreatic ductal adenocarcinoma (PDAC). METHODS Sixty-eight surgically resected formalin(More)
PURPOSE The diagnosis of pancreatic cystic lesions has increased dramatically. Most are benign, whereas some, such as intraductal papillary mucinous neoplasms (IPMN), represent precursors of pancreatic adenocarcinoma. Therapeutic stratification of IPMNs is challenging without precise information on dysplasia grade and presence of invasion. We assessed the(More)
OBJECTIVES Current diagnostic tools for pancreatic cysts fail to reliably differentiate mucinous from nonmucinous cysts. Reliable biomarkers are needed. MicroRNAs (miRNA) may offer insights into pancreatic cysts. Our aims were to (1) identify miRNAs that distinguish benign from both premalignant cysts and malignant pancreatic lesions using formalin-fixed,(More)
Since their discovery, microRNAs (miRNAs) 20 have shown great promise in a wide array of clinical applications. In some cases, the use of miRNAs as new diagnostic markers might help answer diagnostic dilemmas that gene expression analyses or other types of analyses have not been able to satisfactorily address. In other instances, it is easy to perceive(More)
  • 1